TherapeuticsMD (NASDAQ:TXMD – Get Free Report) and Nutriband (NASDAQ:NTRB – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Profitability
This table compares TherapeuticsMD and Nutriband’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
| Nutriband | -430.35% | -109.07% | -95.54% |
Institutional and Insider Ownership
30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 52.2% of Nutriband shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TherapeuticsMD | $3.02 million | 8.24 | -$570,000.00 | $0.02 | 107.50 |
| Nutriband | $2.04 million | 40.27 | -$8.23 million | ($0.53) | -12.75 |
TherapeuticsMD has higher revenue and earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
TherapeuticsMD has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for TherapeuticsMD and Nutriband, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
Summary
TherapeuticsMD beats Nutriband on 8 of the 12 factors compared between the two stocks.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
